Opinion|Videos|December 22, 2025
Safety and Optimal AE Management of Lenvatinib Plus Pembrolizumab in Endometrial Cancer
Author(s)Ramez N. Eskander, MD
Explore the effective management of recurrent endometrial cancer with lenvatinib and pembrolizumab, emphasizing patient education and multidisciplinary care.
Advertisement
Episodes in this series
Ramez N. Eskander, MD, discusses the safety profile of lenvatinib plus pembrolizumab in patients with previously treated advanced endometrial cancer. He covers the safety profile from the 5-year follow-up of Study 309/KEYNOTE-775 and then explains optimal management of adverse events in patients treated with the combination.
Advertisement
Related to this article
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
The antibody-drug conjugate sofetabart mipitecan showed efficacy and safety, leading to selection of a phase 3 dose for the FRAmework-01 trial.
FDA grants orphan drug designation to onvansertib for relapsed or refractory CMML, boosting development of the PLK1 inhibitor after early signals of activity.
Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5